.svg){kind=small}
Where to Buy
Foy is stocked at 117 licensed dispensaries across New York, with the deepest coverage in New York, Queens, Astoria, Brooklyn, and Albany. Search by ZIP code or city below to find the closest one.
Market Insights Snapshot
In July 2026, Foy’s mix is concentrated entirely in Edible at 100.0% share, with category sales up 6.10% year over year but down 2.99% month over month, while brand-level sales rose 5.97% YoY and its average price climbed 17.22% YoY. The average item price at $23.22 coincides with a MoM dip in category sales of 2.99% and a category rank position of 17 in Edible in New York, implying that price-led YoY gains are offsetting recent volume softness and that concentration risk is rising as all growth hinges on a single format.
The divergence between a 17.22% YoY price increase and a 6.10% YoY category sales lift, alongside a 2.99% MoM contraction in category sales and a 5.97% YoY brand sales increase, implies Foy is leaning on mix and price rather than expanding unit velocity. Holding the 17th rank in Edible in New York while maintaining a 100.0% category share mix suggests the current positioning is mid-pack and price-sensitive; sustaining growth will likely require either unit recovery within Edible or selective diversification to reduce exposure to month-to-month Edible swings.
Competitive Landscape
Foy sits at #17 in NY Edible for July 2026, down 3 positions from #14 year over year, while holding flat versus April 2026 at #17; that slippage contrasts with Camino moving from #2 to #1 and Off Hours sliding from #1 to #2 as its sales fell 10.4% year over year. With Foy’s peak at #14 reached in July 2025 and no rank change over the past three months at #17, the combination of a 3-place YoY decline and stable short-term ranking implies the brand is stuck in a mid-tier plateau while leaders are either consolidating share upward (e.g., Camino’s +1 rank and +16.0% sales YoY) or ceding ground (e.g., Off Hours’ -1 rank), suggesting Foy must catalyze a step-change to reenter the top-15 rather than relying on competitor volatility.
Notable Products
CBD/THC/CBN 1:1:1 Night Time Sleep Strawberry Chews 4-Pack (20mg THC, 20mg CBD, 20mg CBN) posted a 160% month-over-month surge and sits at rank 4, while CBD/THC/CBC 1:1:1 Good Mood Peach Chews 20-Pack (100mg CBD, 100mg THC, 100mg CBC) climbed 88% to rank 3, indicating a pivot toward multi-cannabinoid novelty within Edibles. At the top, CBD/THC/CBN 1:1:1 Night Time Strawberry Adaptogen Chews 20-Pack (100mg THC, 100mg CBD, 100mg CBN) retained rank 1 despite an 11% decline, and the CBD/THC/CBG 1:1:1 Daytime Mango Blood Orange Chews 20-Pack fell 11% at rank 2, while a legacy Strawberry Gummy 20-Pack dropped 16% at rank 6. Four of the top seven SKUs are Night Time or Daytime 1:1:1 formulations and one 4-Pack variant fell 55% to rank 7, which creates a barbell where entry 4-Packs either accelerate or retract sharply against 20-Packs anchoring share. The pattern implies Foy’s Edibles mix is consolidating around 1:1:1 cannabinoid stacks with premium 20-Packs defending rank positions while smaller trial sizes create volatile demand spikes, guiding assortment toward maintaining hero 20-Packs and selectively pruning underperforming 4-Packs.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
